Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Advocate Aurora Health
2017-08-01
|
| Series: | Journal of Patient-Centered Research and Reviews |
| Subjects: | |
| Online Access: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1453&context=jpcrr |
| _version_ | 1797934575636185088 |
|---|---|
| author | Michael A. Thompson Martin K. Oaks Maharaj Singh Karen M. Michel Michael P. Mullane Husam S. Tarawneh Angi Kraut Kayla J. Hamm |
| author_facet | Michael A. Thompson Martin K. Oaks Maharaj Singh Karen M. Michel Michael P. Mullane Husam S. Tarawneh Angi Kraut Kayla J. Hamm |
| author_sort | Michael A. Thompson |
| collection | DOAJ |
| description | Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Response rate differences were not statistically significant in this small pilot, and there was no relationship between responsiveness to PV and initial serum total IgG levels or IgG subclasses at study entry. Future prospective studies are needed to ascertain the immunological and clinical efficacy and effectiveness of various vaccines and vaccination strategies in MM. |
| first_indexed | 2024-04-10T18:02:13Z |
| format | Article |
| id | doaj.art-f5d1f077220c45c1aeac380556364784 |
| institution | Directory Open Access Journal |
| issn | 2330-0698 |
| language | English |
| last_indexed | 2024-04-10T18:02:13Z |
| publishDate | 2017-08-01 |
| publisher | Advocate Aurora Health |
| record_format | Article |
| series | Journal of Patient-Centered Research and Reviews |
| spelling | doaj.art-f5d1f077220c45c1aeac3805563647842023-02-02T15:28:58ZengAdvocate Aurora HealthJournal of Patient-Centered Research and Reviews2330-06982017-08-014313113510.17294/2330-0698.1453Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody ResponseMichael A. Thompson0Martin K. Oaks1Maharaj Singh2Karen M. Michel3Michael P. Mullane4Husam S. Tarawneh5Angi Kraut6Kayla J. Hamm7Aurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIAurora Health Care, Milwaukee, WIInfections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Response rate differences were not statistically significant in this small pilot, and there was no relationship between responsiveness to PV and initial serum total IgG levels or IgG subclasses at study entry. Future prospective studies are needed to ascertain the immunological and clinical efficacy and effectiveness of various vaccines and vaccination strategies in MM.http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1453&context=jpcrrmultiple myelomavaccinationpneumococcalclinical efficacyimmunologyantibodyimmunoglobulin G |
| spellingShingle | Michael A. Thompson Martin K. Oaks Maharaj Singh Karen M. Michel Michael P. Mullane Husam S. Tarawneh Angi Kraut Kayla J. Hamm Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response Journal of Patient-Centered Research and Reviews multiple myeloma vaccination pneumococcal clinical efficacy immunology antibody immunoglobulin G |
| title | Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response |
| title_full | Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response |
| title_fullStr | Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response |
| title_full_unstemmed | Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response |
| title_short | Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response |
| title_sort | multiple myeloma baseline immunoglobulin g level and pneumococcal vaccination antibody response |
| topic | multiple myeloma vaccination pneumococcal clinical efficacy immunology antibody immunoglobulin G |
| url | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1453&context=jpcrr |
| work_keys_str_mv | AT michaelathompson multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT martinkoaks multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT maharajsingh multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT karenmmichel multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT michaelpmullane multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT husamstarawneh multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT angikraut multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse AT kaylajhamm multiplemyelomabaselineimmunoglobulinglevelandpneumococcalvaccinationantibodyresponse |